Creating Impact Together
Progress is built on collective contributions.
Ichnos Sciences is interested in working with collaborators with bold ideas and capabilities that complement and stretch our potential to shift progress, advance science, and deliver transformative medicines.
We are open to discussing partnerships on our oncology portfolio and have out-licensing opportunities available for our autoimmune disease assets. Explore the pipeline chart below to learn more about these assets and their potential indications.
Interested in partnering or out-licensing? Contact us at Corporate.Communications@ichnossciences.com.
Autoimmune Disease
| Candidate | Target | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
|---|---|---|---|---|---|---|
| ISB 830 (telazorlimab) | OX40 antagonist monoclonal antibody | Phase 2b completed† | ||||
| ISB 880 | IL-1RAP antagonist monoclonal antibody | IND-Enabling Studies |
autoimmune-disease
-
Compound:ISB 830 (telazorlimab)Target:OX40 antagonist monoclonal antibodyIndication:Atopic Dermatitis (AD)*
-
Status:Phase 2b completed†
-
Compound:ISB 880Target:IL-1RAP antagonist monoclonal antibodyIndication:Autoimmune Disease
-
Status:IND-Enabling Studies
*A US IND for rheumatoid arthritis and other autoimmune indications is active.
†Primary efficacy endpoint (EASI score, % change, baseline to week 16) met at two highest doses tested. Numerical improvements were seen for the two higher-dose arms (300 mg and 600 mg q 2 weeks) of telazorlimab compared to placebo in the secondary endpoints of EASI-75 and Investigator Global Assessment, but the differences were generally not statistically significantly different from placebo.
Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.
View Career Opportunities
The links above are provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.
